[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

A new drug that reduces the risk of breast cancer recurrence has been approved in England. According to an analysis by the ...

There are several different types of anti estrogen supplements available, including aromatase inhibitors, selective estrogen receptor modulators (SERMs), and estrogen blockers. Each of these ...

A new twice-daily pill has been approved for NHS use, offering a significant reduction in the risk of certain breast cancers ...

Panelists discuss how testing for specific changes in cancer cells, like ESR1 mutations, can help guide treatment choices for patients with hormone receptor-positive metastatic breast cancer.

Essential Tools for Managing Hormone Receptor-Positive Breast Cancer Presented by Learn Look Locate and Walgreens “We know ...

STAAR Low-Grade Serous Ovarian Cancer Foundation and Not These Ovaries Fund Breakthrough Research at MD Anderson Cancer ...

AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...